Category: European Union
-
Samsung, Headwater settle wireless patent dispute
Samsung and Headwater Research have settled a two-year patent infringement dispute.
-
Pharma and Biotech Patent Litigation Summit Europe returns in 2026: rebranded event features tech industry track, UPC litigation forum
Kisaco Researchâs annual Pharma and Biotech Patent Litigation Summit Europe will take place from January 19 to January 21 in the Beurs van Berlage, Amsterdam, with ip fray as an official media partner.
-
An interview with Bayerâs outgoing head of IP Dr. Jörg Thomaier, new head Dorian Immler
Following three decades at Bayer, Dr. Jörg Thomaier is retiring as head of IP, super confident that his replacement Dorian Immler will have the energy and drive to make the changes that the department needs to keep prospering.
-
IP Europe, Nokia welcome definitive withdrawal of EU SEP Regulation
Apparently the formal withdrawal of the proposed EU regulation on standard-essential patents already happened weeks ago, and its publication is now imminent.
-
Podcast: interview with ETSI director-general Jan Ellsberger on focus beyond telecoms, including AI, quantum
The European Telecommunication Standards Institute (ETSI) is an independent not-for-profit body dedicated to ICT standardization that addresses market needs expressed by more than 900 ETSI members located in well over 60 countries around the world, while at the same time developing standards in support of the EU legislation. On the occasion of the recording of…
-
Litigation funders are âcentralâ to class action regime, says UK Competition Appeal Tribunal chairman Hodge Malek KC
âWe donât want to kill off the industry [and] we want the best for everyone, including the funders,â Mr. Malek said at the 2nd Annual LF Dealmakers Europe in London yesterday.
-
AI patent-eligibility: spotting hallucinations over value-adds
While AI is accelerating discovery, designing software, and shaping new chemical compounds, some industry voices question whether we have become too dependent on it to invent, and how the pitfalls of that over-dependence are being materialized.
-
Novo Nordisk lets key Ozempic patent lapse in Canada, despite being worldâs second-largest semaglutide market
Novo Nordisk has continued to pay for a key Ozempic patent in several jurisdictions across the world, and even obtained an adjusted expiration date in the U.S., but the company stopped paying fees in Canada as far back as 2018, records show.
-
Standardization âindispensableâ in making Europe the âquantum continentâ: ETSI responds to proposed EU quantum strategy
ETSI is among 168 respondents to the EUâs call for evidence on its incoming Quantum Strategy, which is aiming to make Europe take the lead in the global quantum race, with some stating that enhancing IP commercialisation mechanisms will also be key.